Heart Failure in Norway: Clinical Characteristics, Mortality and Health Care Resource Use


The prevalence of Heart failure above 70 years of age is 10% and 5 year mortality rate above 60%, higher than for cancer. The readmission rate first after hospitalisation is 44% despite the availability of life prolonging and life quality enhancing treatment. There is a lack of resources for adequate diagnostic workup necessary for implementing evidence-based treatment. This projects aims at assessing the impact of guidelines based diagnostic workup and guidelines based treatment of heart failure on mortality and readmission rates. As the symptoms defining the degree of heart failure and the discharge medication only is available in the electronic patient files, artificial intelligence is used to retrieve this information to assess if treatment is according to guidelines. The project is using first a rule based text processing approach using IBM Watson, then advancing to a machine learning approach using readmission and mortality as endpoints. The project has access to digitally stored echocardiographic measurements as well as digital ECG's and lab data on 15 000 patients admitted with a diagnosis of Heart failure. If the retrieval of symptoms and function by artificial intelligence is successful, the next step is to assess if those benefitting the most from echocardiography can be identified using information from the ECG's, lab data or symptoms and functional capacity as described in the Electronic Health Records.

Full Title of Study: “Heart Failure in Norway: Combining Artificial Intelligence and a Database of 15000 Patients to Understand Clinical Characteristics, Mortality and Health Care Resource Use”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: June 2021

Clinical Trial Outcome Measures

Primary Measures

  • Mortality
    • Time Frame: Change over 12 years
    • 1 year mortality rate after first diagnosis of heart failure
  • Readmission
    • Time Frame: Change over 12 years
    • 30 days and 1 year readmission rate

Secondary Measures

  • Diagnostic work up according to guidelines
    • Time Frame: Within 6 months before or after first diagnosis
    • Proportion with echocardiography and other necessary investigations
  • Treatment according to guidelines
    • Time Frame: within first year after first diagnosis
    • Proportion treated according to guidelines

Participating in This Clinical Trial

Inclusion Criteria

Diagnosis with ICD10 codes as follows; I50.*, I42.3, I11.* and COPD J44.* from 2007 through 2019. In addition all subjects with NT-proBNP above age specific normal range in same period. Exclusion Criteria:


Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Akershus
  • Collaborator
    • Novartis
  • Provider of Information About this Clinical Study
    • Principal Investigator: Torbjorn Omland, Professor – University Hospital, Akershus
  • Overall Official(s)
    • Henrik Schirmer, MD, PhD, Principal Investigator, University Hospital, Akershus

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.